Clinical Trial Update: COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study [Phase 2]

View source ↗

Summary

Phase 2 CPAT-SG trial evaluating protection against COVID-19 after kidney transplantation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: COVID-19, Kidney Transplant | Phase 2 | Status: COMPLETED | Results posted: 2025-06-25